Why It Matters

Boston Scientific Corp. Q3 2025 spending $570,000 reflects sustained commitment to influencing several critical policy areas directly affecting device innovation and market access.

The company is aiming to position itself to significantly impact emerging legislative priorities. Congress is actively advancing bipartisan bills on Medicare coverage for breakthrough technologies—addressing the "valley of death" between FDA approval and reimbursement that historically has delayed patient access by years. Boston Scientific’s long-standing focus on Medicare/Medicaid reimbursement (26 historical disclosures) positions it to shape how these new coverage pathways ultimately function. The Ensuring Patient Access to Critical Breakthrough Products Act and companion House legislation face implementation challenges around fraud prevention and device scope that will require sustained industry input.

The company’s spending level remains consistent with its historical patterns, suggesting stable long-term commitment rather than surge investment. However, its $32.4 million in-house spending (77 reports) demonstrates strategic preference for direct control over federal engagement, complemented by selective external partnerships for specialized expertise.

By the Numbers

Boston Scientific spent $570,000 in Q3 2025 lobbying expenditures, continuing two decades of sustained federal advocacy. The company has maintained a dominant in-house lobbying operation since 2003, filing 77 reports and spending $32.4 million internally—the vast majority of its total $37 million lobbying investment.

Historically, Boston Scientific has focused on health and reimbursement issues (76 disclosures), taxation (71 disclosures), trade policy (66 disclosures), veterans affairs (53 disclosures), and transportation regulations (49 disclosures). The company complements its in-house team with external partners including Alston & Bird LLP (healthcare, tax, trade), Brick Street Strategy LLC (VA supply chain), and Hollier & Associates LLC and Quickel Consulting Services LLC (international tax reform). The Q3 2025 filing does not identify individual in-house lobbyists or their prior experience.

The Agenda

Boston Scientific has refined its lobbying strategy in recent years, adding specialized external partners to address emerging policy priorities. The company engaged Hollier & Associates LLC and Quickel Consulting Services LLC in 2024 specifically for international tax reform and Tax Cuts and Jobs Act reauthorization. Most recently, it hired Alston & Bird LLP in 2025 to handle healthcare reimbursement, tax, and trade issues—signaling heightened focus on escalating tariff uncertainty and supply chain pressures. This represents a calculated expansion rather than a departure from strategy.

The current legislative environment features significant bipartisan momentum on issues directly aligned with Boston Scientific’s priorities, including the Ensuring Patient Access to Critical Breakthrough Products Act and the Medical Supply Chain Resiliency Act.

Boston Scientific’s Q3 2025 Lobbying Activity

Broader Context

Congress is actively advancing policies directly aligned with Boston Scientific’s core business priorities. Bipartisan momentum behind breakthrough device coverage legislation addresses the industry’s long-standing complaint about delays between FDA approval and Medicare reimbursement—averaging 5.7 years currently.

The House Ways and Means Committee advanced the measure with overwhelming bipartisan support (38-3). Additionally, Congress is considering regulatory modernization bills, including measures addressing electronic device labeling and AI-enabled medical devices. The Medical Supply Chain Resiliency Act targets trade barriers affecting medical goods, aligning with Boston Scientific’s historical focus on trade policy.

Boston Scientific operates within a broader advocacy coalition. AdvaMedMedical Device Manufacturers Association and peer companies including Zimmer Biomet and Cook Group are actively lobbying on shared priorities around breakthrough device coverage, electronic labeling, and supply chain resilience.

Between The Lines

Congress is actively advancing legislation directly aligned with Boston Scientific’s core lobbying priorities. The Ensuring Patient Access to Critical Breakthrough Products Act and companion H.R.5343 are gaining bipartisan momentum, with the House Ways and Means Committee approving the measure 38-3.

However, the company faces emerging headwinds. Trade policy uncertainty—including a 10% global tariff and Section 232 investigation into medical devices—threatens supply chains. Environmental regulations on ethylene oxide sterilization, delayed by two years, remain unsettled. FDA approval capacity is strained, with high-risk device approvals hitting a ten-year low.

Competitive Landscape

Boston Scientific operates within a highly competitive advocacy environment where numerous medical device manufacturers and trade associations are actively lobbying on overlapping policy priorities. The Medical Device Manufacturers Association and Advanced Medical Technology Association (AdvaMed) consistently advocate on FDA approval processes and device sterilization issues. Peer companies including Philips Electronics North America Corp., Zimmer Biomet Holdings Inc., Dexcom Inc., and Cook Group Inc. are actively lobbying in support of breakthrough device coverage legislation and the Medical Device Electronic Labeling Act. Additionally, companies like Zimmer Biomet and Cook Group are heavily engaged on environmental regulations concerning ethylene oxide sterilization and PFAS chemicals, indicating a broader industry-wide focus on addressing evolving regulatory pressures beyond traditional reimbursement and innovation issues.

Bottom Line

Boston Scientific’s Q3 2025 lobbying expenditure of $570,000 reflects the company’s continued engagement on core policy priorities amid active congressional focus on medical device innovation and market access. The company’s historical lobbying portfolio—spanning healthcare reimbursement, trade, taxation, and veterans affairs—aligns with current legislative momentum on Medicare coverage for breakthrough devices, regulatory modernization, and supply chain resilience. While these policy developments present opportunities aligned with Boston Scientific’s business interests, the company also faces emerging challenges including tariff uncertainty, environmental regulations, and FDA capacity constraints.

Spot something wrong? Report an issue with this article